According to the amyloid cascade hypothesis, accumulation of the amyloid peptide A␤, derived by proteolytic processing from the amyloid precursor protein (APP), is the key pathogenic trigger in Alzheimer's disease (AD). This view has led researchers for more than two decades and continues to be the most influential model of neurodegeneration. Nevertheless, close scrutiny of the current evidence does not support a central pathogenic role for A␤ in late-onset AD. Furthermore, the amyloid cascade hypothesis lacks a theoretical foundation from which the physiological generation of A␤ can be understood, and therapeutic approaches based on its premises have failed.
Introduction
Alzheimer's disease (AD) is the most common form of dementia in the United States, representing around eighty percent of all cases. As the country's sixth leading cause of death, AD currently affects 5.4 million Americans, or one in eight people 65 or older (Alzheimer's Association, 2011). With no cure or effective treatment, AD incurs an estimated annual cost of $183 billion (Alzheimer's Association, 2011). As the US population continues to age, the number of individuals with AD is projected to increase to 7.7 million over the next twenty years (Alzheimer's Association, 2011) .
Affirmative diagnosis of the disease is only possible at autopsy, when specific pathological hallmarks can be visualized in the brain: extracellular senile plaques (SPs), comprised of the amyloid peptide A␤, and neurofibrillary tangles (NFTs), made from abnormally phosphorylated tau protein. A␤ is a 38-43 amino acid peptide formed through the sequential cleavage of the amyloid precursor protein (APP) by ␤-and ␥-secretases (Hardy and Selkoe, 2002) . The 40 (A␤ 40 ) and 42 (A␤ 42 ) amino acid forms are the most abundant, the latter having the greater tendency to aggregate (Jarrett et al., 1993) .
The amyloid cascade hypothesis
The identification of SPs and NFTs in AD led Hardy, Higgins, and Selkoe to propose the Amyloid Cascade Hypothesis. This hypothesis states that AD initiates when A␤ accumulates and aggregates to form SPs, which in turn induce the formation of NFTs and cell death, thereby causing the pathological presentation and dementia (Selkoe, 1991; Hardy and Higgins, 1992) . For the past several decades, researchers have been guided by the primary prediction of this hypothesis: preventing A␤ aggregation will ameliorate or halt progression of the disease.
Supporting this hypothesis, trisomy 21 (Down syndrome) usually results in three copies of the APP gene, and consistently coincides with AD-like pathology (Masters et al., 1985) . Mechanistic studies have also shown that A␤ accumulation can precede, and lead to, tau phosphorylation and aggregation into NFTs (Hardy and Selkoe, 2002; Jin et al., 2011 ). Additionally, rare forms of familial early-onset AD are linked to specific mutations in APP or to enzymes that promote A␤ aggregation (Hendriks et al., 1992; Scheuner et al., 1996) . Proponents of the amyloid cascade hypothesis have assumed that late-onset AD is mechanistically identical to early-onset, consistently placing A␤ as the origin of pathogenesis in all cases.
Shortcomings of the amyloid cascade hypothesis
Conversely, there is an increasing amount of data contradicting the notion that A␤ is the key pathogenic trigger in late-onset AD, which represents the vast majority of cases (Blennow et al., 2006) . Notably, there is no significant correlation between A␤ accumulation and cognitive deterioration in either humans or in mouse models, and the appearance of SPs has been reported in the brains of approximately thirty percent of individuals with no dementia (Crystal et al., 1988; Price et al., 2009) . Such findings have prompted some to reasonably advocate restructuring AD diagnosis to focus on symptomatic changes rather than the neuropathological identification of SPs and NFTs (Dubois et al., 2010) .
Despite the waning support of the amyloid cascade hypothesis at the mechanistic level, there has been optimism that pharmacologically correcting A␤ abnormalities might nevertheless help cure or slow progression of the disease. The most promising A␤-modifying drugs that have reached clinical trial stages have targeted A␤ production, inhibition of the enzymes involved in its generation (␤-or ␥-secretases), or driving ␥-secretase activity toward the production of shorter, less aggregation-prone forms of A␤ in lieu of A␤ 42 . Other strategies have included the inhibition of A␤ aggregation, the induction of an immune response against it, or enhancing mechanisms of A␤ removal (Golde et al., 2010) . Discouragingly, the clinical trials of these drugs have produced lackluster outcomes. Recent compounds targeting ␥-secretase, such as tarenflurbil, even when successfully reducing A␤ levels, have shown no benefit to cognitive function (Vellas, 2010) . While antibodies targeted against aggregating A␤ have managed to decrease A␤ plaques, there has been no significant change in survival or cognition, NFTs have remained in plaque-free areas, and vascular deposition of amyloid, known as cerebral amyloid angiopathy (CAA), has actually increased (Holmes et al., 2008) . Other immunotherapy treatments have caused vasogenic edema while showing no evidence of therapeutic benefit (Delrieu et al., 2011) . Drugs like scyllo-inositol and homotaurine, aimed at preventing A␤ aggregates from forming into SPs, have failed to mitigate clinical AD progression (Golde et al., 2010; Salloway et al., 2011) .
The amyloid hypothesis is also lacking at the conceptual level, due to the absence of a theoretical framework through which the physiological generation of A␤ and the mechanisms leading to its accumulation are understood. This shortcoming stems from our poor understanding of APP biology; despite the wealth of data on the cellular and molecular mechanisms of APP trafficking and processing, we do not know what the function of APP is in the brain. Until we do, we will not be able to understand why A␤ is generated in the healthy brain, let alone place it within the pathogenic cascade of AD. Nevertheless, current evidence argues against a central pathogenic role for A␤ in late-onset AD; this has been best summarized by Karl Herrup, who recently proposed a model in which neurodegeneration begins with an initiating injury, subsequently leading to microglial dysregulation and inflammatory responses, and, eventually, resulting in a so-called "change-of-state" in cells that primes them for neurodegeneration (Herrup, 2010a) . While this model does not provide specifics on the nature of an initiating injury that would be relevant to the majority of AD cases, it represents a comprehensive interpretation of available data; it identifies A␤ accumulation as a potential part of the process of microglial dysregulation and inflammation that characterizes the AD brain, while rejecting it as neither central to, nor a requirement for, the initiation and progression of the disease (Herrup, 2010a) .
Moving beyond the amyloid cascade hypothesis
The amyloid cascade hypothesis defines AD as a series of pathological hallmarks that are causally linked, both in familial (early-onset) and sporadic (late-onset) cases. It assumes that erasing those hallmarks will restore cognitive function. Current evidence does not support this concept for sporadic cases; rather, the data suggest that A␤ is either too peripheral or too close to the final stages of the disease to be considered the primary initiator of pathogenesis, making it of little therapeutic use. If this view is correct, then likely candidates for bona fide pathogenic triggers in late-onset AD have yet to be identified.
3.1. Cholesterol dysregulation: a common pathogenic trigger in late-onset Alzheimer's disease It is well documented that cholesterol is a key regulator of cellular processes in the brain, including the formation of myelin sheaths, synaptic function, membrane fluidity and neurosteroid biosynthesis; cholesterol homeostasis has also been linked to learning and memory function in both humans and animals (Schreurs, 2010; Valdez et al., 2010) .
It is noteworthy that, while physiological cholesterol synthesis rates and levels in the healthy brain decline more than 40% with age, reflecting the different needs and roles for brain cholesterol at different stages of life, this phenotype is reversed in late-onset AD (Thelen et al., 2006) . Furthermore, there is a strong correlation between levels of brain cholesterol and disease severity in the AD brain (Phelix et al., 2011) . That brain cholesterol levels may evolve differently in healthy elderly individuals and late-onset AD patients is suggestive of a causative role for cholesterol in the pathogenesis of the disease. This causative role is more clearly illustrated by several other lines of evidence. At the cellular level, cholesterol dysregulation can both precede and affect SPs and NFTs, the two key pathological hallmarks of AD: The amyloidogenic processing of APP occurs in cholesterolrich lipid rafts, and cholesterol accumulation can enlarge lipid raft size, thereby increasing A␤ generation (Burns et al., 2003; Cordy et al., 2003) . Supporting this concept, rabbits and APP transgenic mice fed a cholesterol-enriched diet showed increases in A␤ (Sparks et al., 2000; Shie et al., 2002; Ghribi et al., 2006) . Furthermore, anomalies in cholesterol levels and distribution are able to influence the phosphorylation state of tau and create NFTs independently of A␤ (Koudinov and Koudinova, 2001; Liu et al., 2010b; Nunes et al., 2011) .
There is also a well-established link between AD and apolipoprotein E (ApoE), a protein that, in the brain, is involved in transporting cholesterol and other lipids (Bu, 2009) . Individuals homozygous for the 4 allele of the APOE gene, which produces a protein product that is a less efficient transporter than its counterparts, are as much as 18-fold more likely to develop AD (Corder et al., 1993) . More recent genetic evidence in support of cholesterol dysregulation as causative of late-onset AD has been provided by genome-wide association studies. Remarkably, in addition to APOE, four other loci are associated with cholesterol metabolism and/or transport: CLU, ABCA7, LDLR, SORL1 (Jones et al., 2010; Hollingworth et al., 2011; Naj et al., 2011) . A second associated pathway is that of endocytosis, also linked to cholesterol biology (Jones et al., 2010; Hollingworth et al., 2011; Naj et al., 2011) . In that respect, PICALM is of particular interest, as it has been shown to confer risk predominantly in the presence of APOE 4 positive subjects (Jun et al., 2010) .
Other neurodegenerative conditions can also be informative with regards to a potential causative role for cholesterol in brain pathogenesis. Of particular interest is the case of Niemann-Pick type C disease (NPC). In NPC, mutations in one of two genes, Fig. 1 . Cholesterol distress, rather than A␤ accumulation, is the more likely candidate for a bona fide pathogenic trigger in most cases of late-onset AD. Cholesterol distress is defined as some combination of abnormal amounts of cholesterol or its precursors and metabolites, aberrant subcellular localization, or oxidation state (green arrow 1a), and is primarily caused by multiple factors, including age, metabolic stress, and gene polymorphisms. In turn, cholesterol distress prompts activation of an APP-driven adaptive response, through a mechanism involving, in part, the generation of A␤ (green arrow 1b). If the adaptive response from APP is insufficient, cholesterol distress can result in cell dysfunction (red arrow 2a). Cell dysfunction can be defined by the presence of major cellular damage as a consequence of axonal transport disruption, tau phosphorylation and aggregation, inflammatory response, reactive oxygen species, and neuronal commitment to aberrant entry into the cell cycle. Cell dysfunction can in turn affect cholesterol regulation via a mechanism mostly driven by inflammation (red arrow 2b). Note that the pathogenic cascade only initiates after cell dysfunction, leading to synaptic collapse, loss of dendritic mass, and neuronal destruction that results in dementia and death (pathway defined by dark red arrow 4). A␤ oligomers and plaques form when there is an excessive defensive response from APP to chronic cholesterol distress. In a brain where cell dysfunction is already ongoing (i.e. within the pathogenic cascade leading to dementia; dark red arrow 4), excess A␤ affects already-vulnerable neurons, further inducing inflammatory responses, extending oxidative damage, and contributing to tau hyperphosphorylation and aggregation. Vascular A␤ deposition would be NPC1 and NPC2, results in cholesterol and other lipids accumulating in late endosomes and lysosomes (Vance, 2006; Lloyd-Evans and Platt, 2010) . In common with AD, APP is disproportionately metabolized to A␤ in NPC, even forming AD-like plaques in patients carrying the ApoE 4 allele; tau has been observed both in early stages of hyper-phosphorylation and as NFTs that are indistinguishable from those appearing in AD brains (Auer et al., 1995; Saito et al., 2002) . NFTs are also more readily detectable in cell populations most affected by cholesterol accumulation, often forming without any prior deposition of A␤ into plaques, indicative of a direct causative link between cholesterol dysregulation and NFT formation (Love et al., 1995) .
In addition, increased expression of NPC1 has been reported in cortex and hippocampus from AD patients, and some NPC1 polymorphisms have been linked to increased risk of developing AD (Kågedal et al., 2010; Rodríguez-Rodríguez et al., 2010) Finally, loss of one copy of the Npc1 gene in AD mice harboring PS1 and APP mutations leads to accelerated A␤ 42 accumulation, compared to control mice with two copies of Npc1 (Borbon and Erickson, 2011) .
In summary, cholesterol is causally linked to neurodegeneration in late-onset AD at several levels. Besides its direct impact on amyloidogenesis and tau aggregation, a significant number of genes involved in cholesterol homeostasis are associated with AD, and other neurodegenerative conditions such as NPC provide formal proof that cholesterol dysregulation precedes, and leads to, A␤ and tau abnormalities.
Dysregulation of APP as a key contributor to cholesterol-driven pathogenesis in late-onset AD
The biological function of APP in the brain, in particular with regards to the physiological generation of A␤ and the mechanisms leading to its accumulation, are not well understood; this shortcoming weakens the theoretical persuasiveness of the amyloid cascade hypothesis. At the same time, it hinders the progress of alternative views that better explain the role of APP and A␤ in health and disease.
We suggest that a close look at the evidence available indicates a potential role for APP as a regulator of cholesterol homeostasis in the brain through mechanisms including, but not limited to, A␤ generation. The evidence in support of APP as a cholesterol regulator in the brain is multifold. In a mouse model of NPC that faithfully recreates the cholesterol accumulation and disease phenotype observed in human patients, loss of APP leads to an exacerbation of the cholesterol abnormalities seen in NPC brains, which in turn leads to accelerated progression of the disease (Treiber-Held et al., 2003; Nunes et al., 2011) . Furthermore, a comparison of gene expression profiles in pre-symptomatic cerebella of control mice to NPC mice with and without APP reveals that the latter is necessary for appropriate cholesterol synthesis in the post-mevalonate pathway; cholesterol transport; myelination, and cholesterol regulation through modification of histone deacetylase (Castello and Soriano, unpublished).
The cleavage products of APP have also been shown to affect cholesterol synthesis and transport directly: A␤ acts to reduce the size of lipid rafts and decreases cholesterol synthesis by inhibiting the rate-limiting enzyme, HMG CoA reductase (HMGR) (Grimm et al., 2005 (Grimm et al., , 2007 . The remaining intracellular domain (AICD) acts as a transcription factor to suppress production of the cholesterol transporter LRP1 (Liu et al., 2007) . Furthermore, A␤ production is increased in response to 27-hydroxycholesterol, an oxidized, neurotoxic form of cholesterol that is increased in AD brains (Prasanthi et al., 2011; Shafaati et al., 2011) .
Finally, it is noteworthy that APP contains a cholesterol-sensing domain shown to be functional in vitro, thereby providing a potential molecular mechanism by which APP could be involved in regulation of brain cholesterol through HMGR, LRP1, and other cholesterol-associated pathways (Castello and Soriano, unpublished) (Beel et al., 2008 (Beel et al., , 2010 Barrett et al., 2012) .
A new focus: the cholesterol hypothesis of neurodegeneration
The fact that cholesterol dysregulation is causally linked to pathogenesis in the AD brain and that APP may function as a regulator of cholesterol homeostasis lead us to propose a novel model of neurodegeneration. In this model, outlined in Fig. 1 , sustained cholesterol distress, rather than A␤ accumulation, is the more likely candidate for bona fide pathogenic trigger in most cases of lateonset AD.
We define cholesterol distress as some combination of abnormal amounts of cholesterol or its precursors and metabolites, aberrant subcellular localization, or oxidation state, all of which are involved in the pathogenesis of neurodegeneration (Fig. 1 , green arrow 1a) (Kirsch et al., 2003; Mattson, 2009; van den Kommer et al., 2009; Liu et al., 2010a; Prasanthi et al., 2011; Stranahan et al., 2011; Xu et al., 2011; Sato et al., 2012) . This cholesterol distress is primarily caused by multiple factors, including aging, metabolic stress and gene polymorphisms (top of Fig. 1) (Kirsch et al., 2003; Mattson, 2009; Liu et al., 2010a; Suzuki et al., 2010; Prasanthi et al., 2011; Stranahan et al., 2011; Xu et al., 2011; Sato et al., 2012; Stranahan and Mattson, 2012) . In turn, cholesterol distress prompts activation of an APPdriven adaptive response, through a mechanism involving, in part, the generation of A␤ (Fig. 1, green arrow 1b) . The view of A␤ as a protective molecule in the brain has been proposed before, perhaps most vocally and systematically by Smith et al., who have argued that A␤ accumulation is a byproduct of upstream pathogenic events and initiates as a protective response to neuronal insult (Castellani et al., 2009) . Such a notion is also consistent with data showing that A␤ is neuroprotective at physiological concentrations and that A␤ can be generated in response to acute damage caused by ischemia and head trauma (Whitson et al., 1989; Förstl et al., 2010) . Nevertheless, the nature of the stress stimuli that would initiate an A␤ response in late-onset AD remains unclear. Smith et al. have proposed that the underlying stress is of an energetic nature through mechanisms involving oxidative stress (Lee et al., 2007) . In the model we present here, APP is a key part of the protective response against cholesterol distress via A␤ regulation of HMGR and LRP1, and potentially other mechanisms involving cholesterol synthesis, transport or histone deacetylase regulation (Castello and Soriano, unpublished) (Grimm et al., 2005 (Grimm et al., , 2007 Grösgen et al., 2010) .
If the adaptive response from APP is insufficient, cholesterol distress can result in cell dysfunction. Cell dysfunction can be defined by the presence of major cellular damage as a consequence of axonal transport disruption, tau phosphorylation and aggregation, inflammatory response, reactive oxygen species, and neuronal commitment to aberrant entry into the cell cycle -all of which have been shown to occur as a consequence of cholesterol distress (Fig. 1, red arrow 2a) (Koudinov and Koudinova, 2001;  prominent at this stage, contributing to cerebral amyloid angiopathy and microbleeds, exacerbating the pathogenic cascade (dark red loop 5). Note that, where plaques are present in cognitively functional individuals, an excessive adaptive response from APP has generated a large amount of A␤, while successfully defending against cholesterol distress. In this case, cell dysfunction is absent and the formation of A␤ oligomers and plaques does not have an obvious impact on neuronal function (not shown in figure) . In early-onset AD and Down syndrome, A␤ is constitutively overproduced throughout life (or the A␤42/A␤40 ratio is significantly higher), to levels that are sufficient to cause dysfunction (see main text for detailed description). Pappolla et al., 2002; Thirumangalakudi et al., 2008; Zhang et al., 2010; Conejero-Goldberg et al., 2011; Nunes et al., 2011; Stranahan et al., 2011) . Of particular interest is the link between cholesterol and the neuronal cell cycle, an early event in AD known to be a cause, rather than a consequence, of neurodegeneration (Currais et al., 2009; Herrup, 2010b) . Disruption of cell-cycle reentry genes has been reported in young adults homozygous for the 4 allele of the APOE gene (Conejero-Goldberg et al., 2011) . A plausible mechanism for cholesterol-induced cell cycle reentry in AD involves miR-33, a microRNA encoded within SREBP-2 that is involved in the regulation of cholesterol synthesis and uptake, as well as the expression of cell cycle genes -including cyclin D1 (Cirera-Salinas et al., 2012; Mandas et al., 2012) . Specifically, downregulation of miR-33 leads to increased cyclin D1 levels, and could conceivably result in neuronal reentry into the cell cycle (Currais et al., 2009; Cirera-Salinas et al., 2012) . SREBP-2 is downregulated in AD, and since miR-33 levels mirror those of SREBP-2, the resulting increase in cyclin D1 would contribute to an aberrant entry into the cell cycle (Bommer and MacDougald, 2011; Mandas et al., 2012) .
Cell dysfunction can in turn affect cholesterol regulation via a mechanism mostly driven by inflammation (Fig. 1, red arrow 2b ) (Block and Hong, 2005) . Note also that the pathogenic cascade only initiates after cell dysfunction, leading to synaptic collapse, loss of dendritic mass, and neuronal destruction that results in dementia and death (Fig. 1 , pathway defined by dark red arrows 4) (Uylings and de Brabander, 2002; Arendt, 2009) .
Our model accounts for A␤ oligomers and plaques forming when there is an excessive defensive response from APP to chronic cholesterol distress (Fig. 1, red arrow 3) . In a brain where cell dysfunction is already ongoing (i.e. within the pathogenic cascade leading to dementia; dark red arrow 4 in Fig. 1 ), excess A␤ affects already-vulnerable neurons, further inducing inflammatory responses, extending oxidative damage, and contributing to tau hyperphosphorylation and aggregation (Morgan, 2009) . Vascular A␤ deposition would be prominent at this stage, contributing to cerebral amyloid angiopathy and microbleeds, exacerbating the pathogenic cascade (Fig. 1 , pathway defined by dark red arrows 5).
Where plaques are present in cognitively functional individuals, an excessive defensive response from APP has generated a large amount of A␤, while successfully defending against cholesterol distress. In this case, cell dysfunction is absent and the formation of A␤ oligomers and plaques does not have an obvious impact on neuronal function (not shown in Fig. 1 ).
Note that early-onset AD and Down syndrome are fundamentally different from late-onset AD. In the former two cases, A␤ is constitutively overproduced throughout life (or the A␤ 42 /A␤ 40 ratio is significantly higher), in the absence of cholesterol distress. In such instances, the protective role of APP metabolites in the brain is not available, and the sustained overexpression of A␤ accelerates the rate at which cell dysfunction occurs, through a combination of a weaker adaptive response (represented by green arrow 1b in Fig. 1 ) and an accelerated rate at which cell dysfunction occurs (represented by red arrow 2a in Fig. 1 ). Neurodegeneration is further exacerbated by the impact of a higher A␤ load (red arrow 3 in Fig. 1 ) on the pathogenic cascade (represented by dark red arrow 4 in Fig. 1) .
The opposite situation occurs in the case of the recently reported rare mutation within the App gene, A673T (Jonsson et al., 2012) . This mutation is less common in AD patients than in non-demented individuals, and elderly carriers perform better in cognitive tests than do non-carriers. Although the impact of this mutation on the APP and cholesterol metabolite profiles in the brain is unknown, amyloidogenesis from A673T APP is significantly reduced in cultured cells, whereas ␣-secretase cleavage is modestly decreased. These findings are also best accommodated within our model. In mutant carriers, A␤ is underproduced throughout life, while preserving the overall function of APP within the adaptive response to cholesterol distress. As a consequence, there is no A␤ excess secondary to a sustained adaptive response (illustrated in red arrow 3, Fig. 1) , and the potential contribution of A␤ to the pathogenic cascade (dark red arrow 4 in Fig. 1 ) and CAA (loop 5 in Fig. 1 ) is drastically reduced, accounting for the slower rate of neurodegeneration and the delay in AD age of onset, as reported. Note also that the A673T mutation creating a stronger adaptive response is also consistent with the superior performance in cognitive tests of patients with the mutation, who retain cognitive ability for a longer period of time even when they do develop AD.
Broader applications of the cholesterol hypothesis
The status of cholesterol as a critical functional element in the brain predicts that it should also emerge as a risk or causative factor for neurodegenerative conditions other than AD, and the current evidence supports that prediction. In Parkinson's disease (PD) and the related Lewy body dementia, for example, there is a progressive degeneration of dopaminergic neurons, accompanied by intra-neuronal deposition of ␣-synuclein (␣-syn) (Galpern and Lang, 2006) . Increases in cholesterol metabolites have been found in these cells, which, in vitro, promote ␣-syn aggregation (Bosco et al., 2006; Barceló-Coblijn et al., 2007) . As is the case with APP, ␣-syn is able to associate with the cholesterol-containing lipid rafts, and is upregulated in the brain in response to 27-hydroxycholesterol, suggesting that it may be part of an adaptive response to cholesterol distress analogous to that occurring in AD (Fortin et al., 2004; Bar-On et al., 2008) .
Other diseases that have been proposed to be causally linked to cholesterol distress are Huntington's disease, schizophrenia, and autism spectrum disorder (ASD) (del Toro et al., 2010; Ota et al., 2011; Seneff et al., 2011) . Interestingly, ASD has a high coincidence with Smith-Lemili-Opitz syndrome, which is a direct consequence of a defect in cholesterol synthesis (Sikora et al., 2006) .
Finally, in support of cholesterol involvement in a variety of neurodegenerative conditions, ApoE, one of the critical genetic risk factors for AD, also appears as a risk or exacerbating factor for Parkinson's disease, cerebral amyloid angiopathy, tauopathies and other dementias, and even multiple sclerosis (Greenberg et al., 1995; Josephs et al., 2004; Masterman and Hillert, 2004; Martinez et al., 2005) .
In short, there appear to be many instances of neurodegeneration that initiate or interface with a failure of cholesterol regulation. Applying our model, molecules such as ␣-syn, huntintin, and others yet to be discovered would fill the role of APP and A␤ as part of an adaptive response analogous to that proposed for AD. An excessive response to correct cholesterol imbalances would result in protein aggregation, with phenotypic differences determined by the type and nature of cholesterol stress and the adaptive response available in susceptible neuron populations.
Conclusions: a new direction for neurodegenerative research
In 2011, President Barack Obama signed the National Alzheimer's Prevention Act, legislation that aims to establish a coordinated plan to overcome the AD crisis in the United States (Bayh, 2011) . Completion of such a plan in a timely manner requires us to widen the scope of inquiry. Even though current evidence does not support a role for A␤ as an initiator of pathogenesis in late-onset AD, debate continues unabated on the finer details of A␤ pathology, diverting recourses from broad, comprehensive hypotheses that fit more strongly with the available data (Karran et al., 2011; Benilova et al., 2012) .
We have provided evidence that cholesterol distress is likely to be a common early pathogenic factor in late-onset AD and a better target for intervention than A␤. From a therapeutic standpoint, due to the diversity of pathways through which cholesterol distress can occur, it is unlikely that a single treatment will prove beneficial to all AD sufferers. For example, while treatment with cholesterol-lowering statins may show a benefit in individuals with high cholesterol levels, these drugs will not work for patients for whom cholesterol distress is not specifically linked to increased cholesterol levels -a conclusion supported by current studies of this approach . As with cancer treatments, the research and pharmaceutical communities will need to develop cost-effective methods to test for a spectrum of cholesterol abnormalities, including levels, trafficking, oxidation, and synthesis that will form the basis of patient-specific medical care.
